{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":4,"sponsored":0,"items":[{"id":"n_thfhjbb55dws23sd6s4q","seq":1502586,"kind":"article","title":"GE, Danaher, Fresenius, Enhertu: This Week in Healthcare","url":"https://healthcare-digital.com/news/ge-danaher-fresenius-enhertu-this-week-in-healthcare","published":"2026-10-03T08:40:51Z","seen":"2026-10-03T08:40:51Z","lang":"en","source":{"id":"healthcare-digital.com","name":"healthcare-digital.com","domain":"healthcare-digital.com"},"via":"gdelt-gkg-english","topics":["economy","science","health","education"],"entities":[{"id":"Q16831645","name":"Fresenius","type":"org"},{"id":"Q80109553","name":"trastuzumab deruxtecan","type":"org"}],"story":"st_thfhjbb55dws23sd6s4q","category":"economy-business","category_p":0.47,"category2":"science-technology","sentiment":"neutral","tone":0.39,"political":0.02},{"id":"n_e2wkr24mzczskusxau5q","seq":801726,"kind":"article","title":"First-line trastuzumab deruxtecan (T-DXd) in metastatic HER2-mutant NSCLC: DESTINY-Lung04 primary results","url":"https://www.onclive.com/view/first-line-trastuzumab-deruxtecan-t-dxd-in-metastatic-her2-mutant-nsclc-destiny-lung04-primary-results","published":"2026-09-30T01:45:00Z","seen":"2026-09-30T01:46:20Z","lang":"en","source":{"id":"onclive.com","name":"onclive.com","domain":"onclive.com","outlet":{"wikidata":"Q140944690","name":"OncLive","type":"website","designations":["publication","website"]}},"via":"gdelt-gkg-english","topics":["health","economy"],"entities":[{"id":"Q80109553","name":"trastuzumab deruxtecan","type":"other"}],"story":"st_e2wkr24mzczskusxau5q","category":"health","category_p":0.3,"category2":"science-technology","sentiment":"neutral","tone":-0.2,"political":0.08},{"id":"n_qtt6m73gbkpe2gv3trqq","seq":486136,"kind":"article","title":"Enhertu in HER2-Mutant Lung Cancer: The First Year, Side Effects and Sequencing","url":"https://www.curetoday.com/view/enhertu-in-her2-mutant-lung-cancer-the-first-year-side-effects-and-sequencing","published":"2026-09-28T17:40:29Z","seen":"2026-09-28T17:40:29Z","lang":"en","source":{"id":"curetoday.com","name":"curetoday.com","domain":"curetoday.com","outlet":{"wikidata":"Q5014714","name":"CURE","type":"magazine","designations":["magazine","website"]}},"via":"gdelt-gkg-english","topics":["economy","health"],"entities":[{"id":"Q80109553","name":"trastuzumab deruxtecan","type":"other"}],"story":"st_qtt6m73gbkpe2gv3trqq","category":"health","category_p":0.64,"sentiment":"neutral","tone":-0.52,"political":0.03},{"id":"n_w4eqxruiltovvnnh2swq","seq":228489,"kind":"article","title":"Enhertu: NICE Approval Expands NHS Breast Cancer Care","url":"https://healthcare-digital.com/news/enhertu-nice-framework-shift-advances-nhs-womens-care","published":"2026-09-27T10:40:37Z","seen":"2026-09-27T10:40:37Z","lang":"en","source":{"id":"healthcare-digital.com","name":"healthcare-digital.com","domain":"healthcare-digital.com"},"via":"gdelt-gkg-english","topics":["economy","health","education"],"entities":[{"id":"Q80109553","name":"trastuzumab deruxtecan","type":"other"},{"id":"Q918396","name":"National Health Service","type":"org"}],"story":"st_w4eqxruiltovvnnh2swq","category":"health","category_p":0.67,"sentiment":"positive","tone":0.58,"political":0.18}]}